With FDA nod, Regeneron brings an RNAi drug to autoimmune disease
The product of a collaboration with Alnylam, Livsayis is now Regeneron’s first marketed RNAi drug and will compete against established medicines from AstraZeneca and Argenx.
Untick a publication to hide it; your selections are stored in this browser. Journals, preprint servers, consumer brands and other high-volume feeds are off by default.
Daily edition · frozen at 7am Eastern
1784 stories from 385 outlets in 54 countries over the previous 24 hours; 19 were covered by more than one outlet. Permanent link: /edition/2026-11-20
The product of a collaboration with Alnylam, Livsayis is now Regeneron’s first marketed RNAi drug and will compete against established medicines from AstraZeneca and Argenx.
Daily pill daraxonrasib appears to shrink and possibly even eliminate tumours in some patients with one of the deadliest cancers.
Health Policy Watch reported that Africa CDC’s Governing Board was expected to discuss the renewal of Director-General Jean Kaseya’s term on 22 November. African governments should look beyond allegations and rebuttals. Whatever the outcome, they should ask for a documented basis for the decision…
Wipro GE Healthcare, a leading medical technology, diagnostics and digital solutions innovator, has announced the appointment of VS Raghavendra Rao as Managing Director of Wipro GE Healthcare and President & CEO, GE HealthCare South Asia, effective January 4, 2027. VS Raghavendra Rao succeeds…
University of Bordeaux researchers.
The approval culminates a winding development journey for Infilbray, and provides Sanofi with a new source of income ahead of Dupixent’s looming patent expiration.
Chronic traumatic encephalopathy can only be confirmed with an autopsy, but two studies suggest biomarkers in the blood might one day lead to a diagnostic test.
Tartu ülikool, ülikooli kliinikum ja Põhja-Eesti regionaalhaigla allkirjastasid reedel koostöölepingu, et ühiselt arendada patsiendile pakutavat arstiabi, kindlustada valdkonna järelkasvu ning edendada tipptasemel teadus- ja arendustegevust.